Myaing M Nyunt

Summary

Affiliation: Johns Hopkins Bloomberg School of Public Health
Country: USA

Publications

  1. ncbi Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine
    M M Nyunt
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Clin Pharmacol Ther 91:889-95. 2012
  2. ncbi Mapping hypoendemic, seasonal malaria in rural Bandarban, Bangladesh: a prospective surveillance
    Wasif A Khan
    ICDDR, B International Centre for Diarrhoeal Disease Research, Clinical Sciences Division
    Malar J 10:124. 2011
  3. ncbi Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites
    Myaing M Nyunt
    Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Am J Trop Med Hyg 80:528-35. 2009
  4. ncbi Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy
    M M Nyunt
    Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Clin Pharmacol Ther 87:226-34. 2010
  5. ncbi Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers
    Myaing M Nyunt
    Johns Hopkins University School of Medicine, Division of Clinical Pharmacology, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 47:559-65. 2008

Collaborators

  • Craig W Hendrix
  • Nirbhay Kumar
  • Wasif A Khan
  • Gregory Glass
  • Sabeena Ahmed
  • Chai Shawi Prue
  • Douglas Norris
  • Jacob Khyang
  • Malathi Ram
  • Alejandro Cravioto
  • Jasmin Akter
  • Md Zahirul Haq
  • David J Sullivan
  • Rashidul Haque
  • Mohammad Shafiul Alam
  • Timothy Shields
  • David A Sack

Detail Information

Publications5

  1. ncbi Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine
    M M Nyunt
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Clin Pharmacol Ther 91:889-95. 2012
    ..Further studies are warranted to assess changes in quinine pharmacokinetics and treatment outcomes in patients with acute malaria receiving antiretroviral therapy that includes LPV/r...
  2. ncbi Mapping hypoendemic, seasonal malaria in rural Bandarban, Bangladesh: a prospective surveillance
    Wasif A Khan
    ICDDR, B International Centre for Diarrhoeal Disease Research, Clinical Sciences Division
    Malar J 10:124. 2011
    ....
  3. ncbi Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites
    Myaing M Nyunt
    Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Am J Trop Med Hyg 80:528-35. 2009
    ..We conclude that a single dose of 100 mg pafuramidine does not adequately protect non-immune individuals against P. falciparum and shows no clinically or statistically significant evidence of causal prophylactic activity...
  4. ncbi Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy
    M M Nyunt
    Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Clin Pharmacol Ther 87:226-34. 2010
    ....
  5. ncbi Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers
    Myaing M Nyunt
    Johns Hopkins University School of Medicine, Division of Clinical Pharmacology, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 47:559-65. 2008
    ..AMD070, a novel entry inhibitor, is an inhibitor of X4-tropic HIV virus. In vitro data suggested that it is a CYP3A4 substrate and may inhibit CYP2D6 and CYP3A4...